A phase I/II study combining 5-fluorouracil, cisplatin, IFN-α and concurrent EBRT before resection in patients with advanced esophageal cancer resulted in 80% of the patients responding to the therapy but the authors claimed that the contribution of IFN-α to the treatment was uncertain (62). The gene discussed is IFNA2; the disease is esophageal cancer.